Osl asx

OncoSil Medical Limited. Is OSL undervalued compared to its fair value, analyst osl asx and its price relative to the market? For this estimate we use a Discounted Cash Flow model.

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets.

Osl asx

At OncoSil Medical, we are committed to making a positive change through the dedication and compassion of our team. This is why it is important that you get to know the people behind the logo. At OncoSil Medical we have a policy of continuous disclosure. We keep shareholders informed through ASX announcements, the company website, regular newsletters and our annual report. We encourage our shareholders to attend and participate at our annual general meetings. Until recently, he was the Group Chief Operating Officer at Telix Pharmaceuticals ASX:TLX a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Currently, Dr Liberatore is a Strategic Advisor to GlyTherix Ltd, an Australian immuno-oncology company specializing in developing antibody radiopharmaceuticals for solid tumours. In addition, Renzo led the development and set-up of the very first Lu, Y and Sr isotopes radiochemical processes in the industry in the early s. He is responsible for leading the clinical research program on novel provide global clinical evidence for the company. More specifically, Henk has held senior leadership positions in the development of clinical programs for brachytherapy over the past 10 years.

Add to Your Portfolio New portfolio.

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech.

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets.

Osl asx

OncoSil Medical Ltd is an Australia-based medical device company seeking to advance radiation for cancer patients. The Company is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous microparticles suspended in a specially formulated diluent. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. Financial Times Close.

Lucky 31 calculator

Morningstar Investment Conference for Financial Professionals. Participants resources. He has spent the past 30 years in scientific affairs and marketing with a significant emphasis on oncology. Morningstar Indexes. Rewards Risk Analysis. Any information that you receive via FT. Morningstar Investor users sign in here. Morningstar Essentials. Morningstar Investment Conference for Individual Investors. Show more World link World. Has less than 1 year of cash runway.

Market data is provided and copyrighted by Thomson Reuters and Morningstar.

Information Services. Less than half of directors are independent Nov Show more Tech link Tech. See Fair Value and valuation analysis. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. Investment options. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. Top Stories. Cancel Continue. Morningstar equity research methodology. Manager Spotlight. Price Volatility. Already a subscriber? Forecast to breakeven in Sep